Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by analysts at Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued on Friday.

TEVA has been the subject of several other reports. BidaskClub upgraded Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. Cantor Fitzgerald set a $10.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Piper Jaffray Companies set a $16.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday. Finally, Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday. Seven analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average target price of $19.34.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at $17.30 on Friday. The stock has a market capitalization of $15,951.20, a PE ratio of 3.63 and a beta of 0.55. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $38.31. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20.

Several institutional investors have recently made changes to their positions in TEVA. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $106,000. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after acquiring an additional 94 shares during the period. Shelter Mutual Insurance Co bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $133,000. Fayez Sarofim & Co. bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $204,000. Finally, Community Bank & Trust Waco Texas bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $210,000. Institutional investors own 52.05% of the company’s stock.

WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/12/15/teva-pharmaceutical-industries-teva-upgraded-at-goldman-sachs-group.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.